BETA
Magnolia, Texas company commercializing NIMBUS and complementary radiofrequency devices for interventional pain treatment, with additional generator and BVNA technologies in development.
Stratus Medical is a privately held medical device company founded in 2019 and headquartered in Magnolia, Texas. Led by Bret Boudousquie, it focuses on radiofrequency technology for interventional pain treatment. The company announced its acquisition of the NimbusRF business in January 2020.
Its marketed portfolio includes the NIMBUS multitined expandable electrode, Vesta RF cannula and reusable/disposable RF probes. Three original-manufacturer FDA clearances are mapped to these families. Device clearance is distinct from evidence about durable pain relief or superiority over alternative RF techniques.
Stratus announced a US$10 million Series B in February 2026 led by Wasatch Health Partners. Development includes its own RF generator and neurovasis basivertebral nerve ablation system; the company explicitly states these are not FDA cleared. Current annual revenue and total drawn financing remain unconfirmed.
Class II GXI RF lesion devices: Biomerics K121773 and K190259, Minta Medical K090608. Original applicants and present Stratus commercial roles remain distinct. [24][25][26][20][5][7][6][21][16][3]
No matching FDA recall event was identified in the completed company/applicant, linked-identifier and product-name searches. [13][9]
Latest recorded source review: 2026-10-20.
Documented commercial product families.
Insulated cannula with deployable tines used with a compatible RF generator and probe to create a heat lesion. Designed for larger lesion geometry; clinical outcomes depend on anatomy, selection and technique. [21][23]
FDA-clearedMarketed in the current U.S. professional catalog; regional configurations and availability vary.
Cannula offering intended for RF heat-lesion procedures; complements the expandable NIMBUS offering. [22]
FDA-clearedMarketed in the current U.S. professional catalog; regional configurations and availability vary.
Probe configurations and adapter cables supplied for compatible RF lesion generators. FDA listing links both variants to Minta Medical’s original clearance. [19][2][1]
FDA-clearedMarketed in the current U.S. professional catalog; regional configurations and availability vary.
Stratus RF Generator and neurovasis BVNA remain under development and not FDA cleared according to current company disclosures. Series B proceeds support completion and clinical research. Published NIMBUS cohorts are separate from investigational-system validation. [18][16][23]
Company developing its own RF generator; current electrode compatibility with other manufacturers does not establish authorization of this system. [16]
Investigational / in developmentUnder development; company states not FDA cleared and not available for commercial sale.
Development program targeting vertebrogenic low-back pain; financed development and planned clinical research are distinct from commercial availability. [16]
Investigational / in developmentUnder development; company states not FDA cleared and not available for commercial sale.
Wasatch Health Partners led financing for generator and neurovasis development, patent work and a clinical study. The separately disclosed US$25M convertible facility is not assumed fully drawn. [16]
A 2025 paper reports 16-person cross-sectional results with mean nine-month follow-up. Small uncontrolled evidence is separate from comparative superiority claims. [23]
Biomerics’ K190259 cleared Vesta RF Cannula; Stratus subsequently announced first U.S. use. [25]
Stratus announced private-placement financing and acquisition of the NimbusRF business, with Med Venture Holdings identified as lead investor. [28]
Biomerics’ K121773 predates Stratus and is retained as the technology’s regulatory history. [24]
Accessed 10/29/2026